IDWeek 2014: Acute Retroviral Syndrome Linked to Higher HIV Levels in Blood, Gut and Brain

People with acute or very recent HIV infection who experience the flu-like symptoms of acute retroviral syndrome (ARS) have higher levels of HIV RNA and proviral DNA in their blood, colon, and brain tissue, indicating more active viral replication, as well as higher levels of certain inflammatory biomarkers researchers reported at IDWeek 2014 this month in Philadelphia.


HIV R4P: HIV Prevention Requires Supporting and Respecting Key Affected Populations

Supporting, protecting, and involving key populations heavily impacted by HIV -- including gay and bisexual men, sex workers, and people who inject drugs -- is a critical aspect of HIV prevention. Advances in biomedical prevention must be developed in collaboration with and made available to the people who need them most, according to several presentations at the HIV Research for Prevention meeting taking place this week in Cape Town.


IDWeek 2014: NNRTIs and Protease Inhibitors Both Good for First ART, Channeling Affects Choices

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 last week in Philadelphia. A related study shed light on factors affecting choice of initial antiretroviral regimen.


HIV and Hepatitis C Highlights from AIDS 2014

Latest Positive Pulse Newsletter

Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss highlights from this summer's International AIDS Conference, the largest and most comprehensive global meeting on the medical, public health, and social aspects of HIV and AIDS.

Highlights of this overview include the HIV cascade of care, developments in antiretroviral therapy, pre-exposure prophylaxis (PrEP) and other HIV prevention news, and new hepatitis C treatment for people with HIV/HCV coinfection.



IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems

Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.


IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower HIV Rebound After Stopping ART

HIV viral load usually begins to rise again within 4 to 8 weeks after stopping antiretroviral therapy (ART), though starting treatment earlier in the course of infection and using a non-nucleoside reverse transcriptase inhibitor (NNRTI) may delay viral rebound, according to study findings presented at IDWeek 2014 last week in Philadelphia.


HIV Positive Stimulant Users Benefit from Antiretroviral Therapy

People with HIV who use methamphetamine or other stimulant drugs do well on antiretroviral therapy (ART) and appear not to be at greater risk than non-users for AIDS-related or all-cause death overall, but those who use stimulants more than half the time did have a higher risk of progression to AIDS or death, according to a study published in the September 30 Journal of Acquired Immune Deficiency Syndromes.